Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of anlotinib plus epirubicin versus placebo plus epirubicin as first-line treatment for advanced soft tissue sarcoma
CTR20212696Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib, epirubicin in soft tissue sarcoma (STS), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Dec 2021; status: active.
02
Drugs
anlotinibepirubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on CTR20212696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212696.